Abridge vs DeepScribe

DeepScribe and Abridge both leverage ambient AI to automate clinical documentation, but they target different pain points. DeepScribe emphasizes specialty care with its Customization Studio, context-aware notes from past records, and AI coding for E/M, ICD-10, and HCC. Its latest SmartPrep feature (June 2026) pre-charts oncology visits by reviewing labs, imaging, and medications, a boon for longitudinal care. It supports integration with major EHRs like Epic, Cerner, and Athenahealth. In contrast, Abridge focuses on enterprise health systems with a Contextual Reasoning Engine and real-time clinical decision support. It uses OpenAI GPT-5.5 for enhanced reasoning (April 2026) and offers multi-language support in 28 languages—a differentiator for diverse populations. Abridge also provides real-time prior authorization (August 2025) and nursing draft documentation from natural conversation (May 2026). While DeepScribe captures over 5 million oncology visits annually, Abridge boasts over 300 health systems (Kaiser, Johns Hopkins, Mayo). For coding accuracy, Abridge automates billable code capture to increase wRVU, DeepScribe integrates diagnosis intelligence. Both reduce documentation effort, but Abridge claims 86% reduction, citing clinician burnout reduction of 55%.

Both DeepScribe and Abridge operate on a contact-for-pricing model, targeting enterprise health systems and large practices. There are no publicly listed per-user costs, typical for enterprise AI contracts. For small clinics or solo practitioners, both may be expensive and require commitment. DeepScribe's pricing is likely influenced by its specialty focus and customization depth, potentially higher per-user for specialized models. Abridge's enterprise deals often involve institution-wide deployment; its value proposition includes ROI through increased wRVU and reduced burnout. With both, pricing may scale with features like language support, integrations, and volume. There is no free tier or transparent pricing, making it hard for smaller entities to budget. Given the lack of pricing transparency, organizations must request quotes and evaluate total cost based on deployment scope.